CPC A61K 9/0048 (2013.01) [A61K 31/196 (2013.01); A61K 31/4709 (2013.01); A61K 31/496 (2013.01); A61K 31/573 (2013.01); A61K 31/58 (2013.01); A61K 38/12 (2013.01); A61K 38/14 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61K 47/22 (2013.01); A61K 47/38 (2013.01)] | 4 Claims |
1. A pharmaceutical composition, comprising:
(a) a therapeutically effective quantity of triamcinolone or a derivative thereof;
(b) a therapeutically effective quantity of moxifloxacin;
(c) a non-ionic poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) block copolymer having a molecular weight of the polyoxypropylene portion of about 4,000 Daltons and about a 70% polyoxyethylene content, with an overall molecular weight of between about 9,840 Daltons and about 14,600 Daltons, wherein the concentration of the non-ionic poly(ethylene glycol)-block-poly(propylene glycol)-block-poly(ethylene glycol) block copolymer is between about 1 mass % and about 2 mass % of the pharmaceutical composition;
(d) about 1% of polysorbate 80; and
(e) a pharmaceutically acceptable carrier.
|